In 2017, a Nature paper got a lot of attention due to the claim by the Stanford authors that the CRISPR-based gene editing technique may cause widespread genetic damage when used in vivo. The authors have just retracted this paper, after concerns were raised that the proper controls had not been employed.
23andMe CEO Anne Wojcicki has published an Op-ed critique of the position that consumers cannot interpret their own genetic risk scores. Recently, the FDA approved 23andMe’s genetic test for inherited cancer. There was some criticism of this, which Wojcicki compares to the warnings forty years ago that women might not be able to handle the results of those first home pregnancy tests.
Check out our conference page for updates from Canada SynBio 2018 including presentations, highlights and photos from the conference.
-Conference Presentations can be found by clicking on the active links under each session in the SynBio Agenda.
-Conference Highlights can be found in our SynBio Feature.
-Additional Photos from the conference can be found in our SynBio Page and Photo Album.
Ontario’s diverse agriculture, agri-food and aquaculture sectors are the focus of three new funding opportunities. All of these new project funding opportunities require partnering researchers together with end-users in their respective sectors. We work directly with researchers, and end-users to: access funding find and connect with the right research and/or end-user partners help develop competitive…
Genome Canada has partnered with the Canadian Institutes of Health Research (CIHR) to launch a funding opportunity to support a national network that will help maintain Canada’s leadership in enabling clinical geneticists who are identifying rare disease gene mutations to collaborate with model organism researchers with expertise in the cognate gene’s function, and to develop…
Richard Beauchamp is cancer free despite his pancreatic cancer diagnosis in 2014. Beauchamp learned that, in his case, his French Canadian genes held a clue to an effective treatment when he enrolled in the pan-Canadian clinial trial EPPIC. EPPIC aims to sequence the tumours of pancreatic cancer patients across the country and provide personalized treatment based on their particular subtype of the disease. Beauchamp and others are seeing the benefits of this approach.
Air pollution leaves its mark on the human body, a newly published Canadian study, led by Philip Awadalla of the Ontario Institute for Cancer Research in Toronto, has found. For example, the results show that someone who was born in Saguenay but who grew up in Montreal will develop a genetic expression signature along with associated risk factors that more closely resemble those of a native Montrealer. These results may help develop better predictors of disease risk.
With $4.4M in new funding, Dr. Richard Kim and team at Lawson Health Research Institue (LHSC) will follow patient outcomes and assess the cost-effectiveness of LHSC’s personalized medicine program, providing evidence on the relationship between the cost of the program and how patient care is improved. This program focuses on pharmacogenomics, the study of genetic changes that alter the way a person responds to individual drugs.
Dynacare has launched a new and unique genetic test for epilepsy patients. Developed at the London Health Sciences Centre and commercialized through Dynacare, this Canadian innovation success story is paving the way for academic-commercial partnerships.
On March 6 Ontario Genomics, in partnership with ISED Canada and the Genome Canada Enterprise, hosted Canada’s first national conference focused on Engineering Biology. Over 275 people attended the packed MaRS Discovery District auditorium for the event with speakers and attendees from academia, industry and government across Canada, the US and globally. The day was about learning, mobilizing the community, creating opportunities for collaboration and partnership, and ultimately to start charting a course for Canada to capitalize on this emerging area.